Pharmaceutical Executive, Sep 1, 2008 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Sep 1, 2008
Features
Industry Audit + Company of the Year 2008
By Bill Trombetta
Pharm Exec's 7th annual review of the top companies. We slice and dice the numbers to see who's the best a what. (pdf)
Bolder is Better
By Charlene Prounis
As oncology grows, its advertising is growing up—leaving behind the mechanistic images and scientific themes of past campaigns
Place Your Bets
By Joanna Breitstein
The industry is a-changing. Here are eight seminal events that describe how.
Publish or Perish
FDAAA means that you need to register clinical trials—and not only for publication planning
How Do You Solve a Problem Like Manufacturing?
By Patrick Kager , David Williams
Outsourcing saves money—except when it doesn't. Here's how to decide what to do.
Unleash the Dragon 2
By Zhu Shen
Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital.
Columns
Considering Consumer Change: Q&A with Jim Joseph, Saatchi & Saatchi
How will pharma fare in the new age of health and wellness marketing?
The Salesforce Software Shift
The smart way to CRM is through SaaS
Washington Report
Foreign Affairs
By Jill Wechsler
FDA missteps and global outsourcing are drawing Congressional scrutiny and prompting new oversight approaches
From the Editor
Attack of the Junk
By Patrick Clinton
The United States makes the best medicines in the world. In days to come, that could be a problem.
Back Page
The M&A Numbers
By Walter Armstrong
Young & Partners crunches pharma's filings for, the first half of '08. The results? Ask the Japanese
Leadership
Tapping the Fount
By Sander A. Flaum
Leaders don't always manage to do the right thing, but they constantly strive to access the wellspring of integrity within them
Opinion
The Orphan Opportunity
The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains
Toolkit
The New Code
Effective January 1st, sales reps will have a new standard for dealing with doctors the PhRMA way
Global Report
Doing More With Less
By Sarah Houlton
In order to take a big step forward, GSK looks to employ smaller licensing deals and business units

ADVERTISEMENT

Click here